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Purpose of review: Historically, pleural effusions have been attributed to a single cause. There is 
growing recognition that a substantial proportion of pleural effusions may have more than one 
underlying cause. The purpose of this review is to summarise recent findings regarding the diagnosis 
and treatment of effusions secondary to more than one aetiology. 
Recent findings: A recent prospective study identified that 30% of pleural effusions had more than 
one underlying aetiology. With a rising prevalence of cardiovascular and malignant disease, the 
incidence of the complex pleural patient is increasing. The use of biomarkers, including Pro-BNP, 
have been suggested as a way of identifying contributing disease process.  
Summary:  Understanding that there are potentially concurrent causes to a pleural effusion is vital in 
establishing the diagnoses of multiple underlying aetiologies. New diagnostic pathways, with 
increasing use of biomarkers, will be required to identify the complex pleural effusion. Further 
studies on whether the targeting of separate aetiologies improves outcomes will help develop future 
management strategies.  
      
 
Key Points: 
• Pleural effusions secondary to multiple aetiologies are common, accounting for 30% of all 
unilateral effusions.  
• Reaching the diagnoses can be difficult, and requires a high index of suspicion 
• Serum Pro-BNP is useful in identifying a cardiac component, with a serum value of 
>1,500pg/ml suggestive of a cardiac effusion.  
• Further disease-specific biomarkers will be in key in developing a diagnostic algorithm 
Introduction  
 
The incidence of malignant and cardiovascular disease is increasing (1, 2), and with it, the prevalence 
of the complex pleural patient. Patients often present with established comorbidities, such as cancer 
and benign lung disease, together with risk factors for  cardiovascular, renal and metabolic disease, 
which all can interact with each other at the pathophysiological level(3). This can make it difficult for 
the physician to identify the predominant cause of the patients’ symptomatology.   
Whilst traditionally, a pleural effusion has been attributed to a single aetiology, there has increasing 
recognition it may be a result of several interplaying disease processes.  A recent study has supported 
this, demonstrating that 30% of the patients studied with a unilateral effusion had more than one 
underlying aetiology (4). This is likely to be underappreciated due to current diagnostic algorithms and 
tools  which are not designed to identify multiple causes(5). The binary classification of transudates 
and exudates also encourages the notion that the effusion has a singular cause.    
Recognition that multiple processes may be responsible and that  establishing one diagnosis does not 
exclude other causes(6) is key in forming a comprehensive diagnosis. The identification of certain 
contributory causes clearly warrants changes in management approach, whilst in others the  benefits 
are  less clear(4). 
New diagnostic algorithms, likely with an increased role of biomarkers, will be required to identify and 
manage the complex pleural effusion. This article will explore possible diagnostic approaches and 
subsequent treatment options for pleural effusions secondary to multiple aetiologies. 
 
Moving on from the traditional approach  
Unilateral pleural effusions are classically felt to result from a singular disease process, despite having 
over 60 possible causes. The pathogenesis and subsequent clinical evaluation of pleural effusions is 
typically divided into transudative  (increased hydrostatic pressures, decreased oncotic forces or 
decreased intrapleural pressures) or exudates (increased capillary permeability and impaired 
lymphatic drainage) (7) using the three part Light criteria. However these processes do not need to be 
mutual exclusive and it possible for more than one to occur.  
 
There is no specific test to determine the underlying cause of an effusion and the diagnosis is typically 
reached after a step-wise approach of investigations, including clinical evaluation, pleural fluid 
biochemistry, imaging techniques and possibly pleural biopsy. This subcategorises the effusion: 
exudate vs transudate, lymphocytic vs neutrophilic, malignant vs non-malignant. This binary approach 
leaves little room to consider an additional cause behind the pleural effusions.  
This approach has been challenged by increasing recognition that a substantial proportion of pleural 
effusions have dual aetiology. On the background of case studies detailing  pleural effusions with 
multiple contributory factors(6), a prospective study of 126 patients with undiagnosed unilateral 
pleural effusions determined that 30% (38/126) had more than one cause to their effusion(4). Heart 
failure was the most common secondary cause, accounting for 51% (21/41). Pleural infection and 
malignancy contributed 20% (8/41) and 17% (7/41) of secondary causes respectively. Malignancy, 
however, was the commonest primary diagnosis, at 46% (58/126), and 21% (12/58) of patients with 
malignancy had more than one apparent causes. This was not uniform amongst cancer subtypes, with 
41% (7/17) of lung cancer malignant pleural effusions (MPE) thought to have a contributory cause. 
 
The complex pleural effusion 
Identification of multiple aetiologies begins with recognising several key principles: 
1. Multiple processes may be responsible (i.e. avoid causal oversimplification) 
2. Establishing one diagnosis does not exclude other causes(6)  
3. Pleural effusions, and their possible aetiologies, can change with time and the initial cause of 
the effusion (i.e. infection) may exacerbated a further cause (i.e. atrial fibrillation leading to 
decompensated heart failure) 
4. Certain causative factors frequently occur together, as coupling factors, exacerbating one 
another (i.e. hypoalbuminaemia in malignancy). 
 
Consider these two cases:  
Case 1: Malignant Pleural Effusion with parapneumonic and hypoalbuminaemia  
A 76 year old gentleman presented with dyspnoea, febrile episodes (>38⁰C/100⁰F) and with large left 
pleural effusion and consolidation on chest radiograph. He had been under investigation for a solitary 
pulmonary nodule. Blood tests demonstrated raised inflammatory markers (CRP 142mg/L), 
hypoalbuminaemia (albumin 16g/L) and NT-proBNP of 475pg/ml. The fluid biochemistry 
demonstrated exudate, with high LDH 2467U/L, low glucose 1.7mmol/L and pH 7.32.   Pleural cytology 
demonstrated adenocarcinoma (TTF-1 positive), consistent with lung primary. CT demonstrated 
consolidation of left lower lobe, bronchial wall thickening and a left unilateral effusion with no 
proximal mass evident.   The diagnosis was malignant pleural effusion with secondary and 
exacerbating causes of simple parapneumonic effusion and hypoalbuminaemia. He was treated with 
antibiotics and chest tube insertion and referred to lung MDT. 
Case 2: Cardiac effusion with complicated parapneumonic effusion  
A 93 year old lady, with previous clinical diagnosis of heart failure, presented with dyspnoea, in fast 
atrial fibrillation and evidence of fluid overload. Chest radiograph demonstrated bilateral effusions 
and right sided consolidation.  Her blood results demonstrated a CRP of 264mg/L, albumin 28g/L, Na 
122mmol/L, WCC 18.8 109/L (neutrophils 14.4 109/L). Pleural aspiration of the right effusion 
demonstrated a neutrophilic predominant cell type effusion with low pH (6.98), but, interestingly, 
with low pleural protein and LDH level of 24U/L and 328U/L respectively (serum protein 55g/L and 
serum 798g/L). Echocardiogram demonstrated signs of right heart failure (dilated RA, PASP 60mmhg, 
and dilated LA, with persevered LV function). NT-proBNP was >3000pg/ml. The diagnosis with 
pneumonia with complicated parapneumonic effusion precipitating atrial fibrillation, resulting in 
decompensated heart failure. She was treated with antibiotics, anti-arrhythmic medication, diuresis 
and thoracentesis.  
 
 
 
A suspicion of concurrent disease processes should prompt a robust diagnostic workup(4). The first 
step is clinical history and exam. Clinical exam should elicit signs of fluid overload and organ 
dysfunction (heart, renal and liver failure) in particular. Evidence of fluid overload is an indication of 
treatment with diuretics first (8). However, it must be noted that 15% of malignant pleural effusions 
are bilateral effusions (9) and conversely 27% of effusions from CHF are unilateral(10).  
Analysis of pleural fluid by the Light Criteria will help identify the main driving cause of the pleural 
effusion. The strengths and limitations of the Light criteria are well-documented. It is highly weighted 
towards sensitivity in identifying exudative processes and suffers in sensitivity in identifying 
transudates. The can lead to over-diagnoses of transudates as exudates, particularly if the patient is 
on diuretics. Additional techniques, for example  serum-pleural albumin gradient ( >1.2g/dl) improves 
its specificity and sensitivity (11).  Recognising both these limitation and that the Light criteria was not 
designed to detect pleural aetiologies of multiple causes does not diminish its usefulness. A nuanced 
usage of the criteria, combined with clinical acumen, enables the clinicians to determine the primary 
driver of the effusion, without losing focus that there may be more than one cause.  
A cell differential is usually performed to classify the effusion as neutrophilic, lymphocytic, eosinophilic 
or mixed. Whilst, neither category is specific to a particular aetiology, a neutrophilic predominant cell 
type is suggestive of an acute inflammatory cell type, whilst a lymphocytic predominant cell type 
typically represents an more chronic process, for example malignancy or TB. Rapid processing of a 
pleural cell differential can be useful to differentiate between complex parapneumonic effusions and 
malignant effusions. 
Pleural fluid flow cytometry (lymphocyte subset analysis) can be used to be diagnose haematological 
malignancy (8) and there may be a role in its used in an undiagnosed lymphocytic predominant pleural 
effusion, particularly if the patient has a history of haematological cancer (based on local unpublished 
work).  
Pleural fluid is usually sent for cytology to examine for presence of malignant cell. However it is well 
recognised it has a high rate of false negative, with only 60% of malignant pleural effusions 
demonstrating malignant cells. Pleural histology, obtained via percutaneous or thoracoscopy biopsy 
is valuable in investigating for malignancy, though the frequent finding of non-specific pleuritis is often 
not useful. 
Biomarkers  
Biomarkers are increasingly used to help establish the underlying aetiology in the complex patient(3). 
Whilst there is a lack of disease-specific biomarkers available at present, there are several which can 
be useful (see table 1). 
 
Table 1: Use of common Biomarkers in pleural disease 
Biomarker Indication Value Sensitivity Specificity 
Serum Mesothelin(12) ?Mesothelioma >2nmol/l 47% 96% 
Serum NT-proBNP(13) ?CHF >1500pg/mL 95% 95% 
Pleural fluid ADA(14) ?TB >40U/L 92% 90% 
Serum CRP  (+neutrophilic 
effusion)(15) 
?Parapneumonic  
effusion  
>45mg/L 64% 92% 
ADA: Adenosine Deaminase; CRP: C-reactive protein; CHF: Congestive heart disease; TB: Tuberculosis. 
 
NT- ProBNP, a neurohormone secreted by stretched cardiomyocytes in response to increase atrial 
pressure, is used as a biomarker to detect likelihood of heart failure. In patients with pleural effusions, 
its sensitivity and specificity have been found to be 94% with and a likelihood ratio (LR) positive of 
15.2 and LR negative of 0.06 in meta-analysis (13). Though differing values of NT-proBNP were used, 
6 studies used values around 1,500pg/ml as the cut off, with a pooled sensitivity and specificity of 95% 
and 95% respectively(13). Therefore, a  cut-off of NT-proBNP levels of greater than 1,500pg/ml argues 
convincingly for heart failure in patients with pleural effusions (16).  
The prospective study by Bintcliffe et al on unilateral effusions examined the utility of NT-proBNP in 
establishing the diagnosis of heart failure. This study demonstrated a lower sensitivity and specificity 
for primary diagnosis of heart failure (76% and 74% respectively) than reported elsewhere. This was 
likely related to low-pretest probability of heart failure in these patients. It was more useful in 
detecting the contribution of heart failure to the aetiology of pleural effusion, with a sensitivity and 
specificity of 79% and 88% respectively.  BNP levels can be influenced by other comorbidities in the 
complex patient. It is recognised that renal impairment  increases the level of BNP and NT-ProBNP by 
20.6% and 37.7% for every 10-mL/min/1.73 m2 (0.17-mL/s) reduction in estimated GFR(17). BNP 
specificity, for a given cut off, is widely recognise to decease with age, as the level of BNP increases 
with age(18). This does pose difficulties when deciding the cut-off level of NBP, as increasing the cut-
off level to increase specificity will decrease sensitivity(18).  
C-reactive protein (CRP) is an acute phase reactant protein that is raised in systemic inflammation.  It 
can be used to suggest an infectious aetiology in pleural effusions, particularly when combined with 
other tests. The combination of neutrophilic pleural fluid and a CRP >45mg/l is highly suggestive of 
pleural infection (LR =7.7) (15).  However, CRP is often significantly elevated in malignancy as well.   
The biomarker, procalcitonin, is recognised as a maker of bacterial infection, and has been used to 
determine length of antibiotics in bacterial chest infections(19). There have been conflicting results 
on its use in differentiating between parapneumonic and non-parapneumonic effusion (20-22) and it 
is not routinely used.  
 
Tumour markers have traditional had a limited role in the diagnosis of pleural effusions. Tumour 
markers (carcinoembryonic antigen (CEA), cancer antigen 125 (CA 125), carbohydrate antigen 15–3 
(CA 15–3), and cytokeratin 19 fragments (CYFRA 21–1)) have low individually sensitivity in diagnosing 
malignancy in pleural effusions (<30%), and when combined their sensitivity, at 50%(23), is lower than 
that of pleural cytology. Mesothelin, as a diagnostic marker for mesothelioma, has a high specificity 
but poor sensitivity in differentiating between high risk controls(12). So whilst a high mesothelin level 
should prompt further investigation, a low measurement in not reassuring.  
There a several biomarkers useful when a particular disease process is suspected. Triglycerides (TG)  
and chylomicrons are useful in determining the presence of chylothorax or pseudochylothorax, with  
over 85% of patients with a chylothorax having a TG levels >110mg/dl and <3% will have a value 
<50mg/dl(24) .   Amylase, whilst suggestive of an effusions caused by pancreatitis, or oesophageal 
perforation, the commonest cause of a high amylase is malignancy(25) and the routine measurement 
pleural fluid amylase has not be found to be helpful in achieving a diagnosis(26).  Pleural Antinuclear 
Antibody (ANA) in pleural strongly supports the diagnosis of lupus pleuritis(27).  Adenosine Deaminase 
(ADA) is useful in determining the presence of tuberculosis and been shown to be more  sensitive and 
specific (92% and 90% respectively(14)) than the  microbiology of both in sputum  and pleural fluid 
(28) (29). However, other diseases can demonstrate high pleural fluid ADA levels, most commonly 
parapneumonic effusions, empyema and lymphomas, with one study demonstrated high ADA levels 
in 44%, 70% and 57% of this conditions respectively(30).  
 
The biomarkers that are available are mainly of use in diagnosing the uncommon causes of pleural 
effusions. It is unclear how sensitive, specific and cost-effective a panel of these biomarkers would be 
in reaching final diagnoses(5). NT-Pro-BNP is a proven biomarker in heart failure and we would suggest 
that a result of >1500pg/ml should prompt further investigation for heart failure as a contributory 
cause. A raised CRP, particularly in the presence of a neutrophilic effusion, is suggestive a 
parapneumonic process.  
 
 
 
Features suggestive of more than one aetiology: 
 
 
Figure 1: Venn diagram of common interplaying pathophysiologies of pleural effusion 
 
Raised NT-ProBNP 
The study by Bintcliffe et al (31) found that over half of the secondary contributory diagnoses were 
heart failure. As discussed above, NT- ProBNP has been shown to be an effective biomarker for 
diagnosing heart failure in pleural disease. Whilst, its sensitivity and specificity is lower when applied 
indiscriminately to all pleural effusions, when there is a suspicion of heart failure, a value of greater 
than 1500pg/ml should prompt investigation with an echocardiogram.  
Conversely, with approximately 5% of malignancy identified as transudates(32), a transudate with 
features suggestive of another cause (i.e. CT features, low pH, raised CRP) should raise the suspicion 
of more there than one underlying process (see Fig 1). 
 
 
 
Hypoalbuminaemia 
Low albumin is not uncommon in patients with pleural infection and malignancy and is a marker of 
severity in pleural infection(33)  Whilst the presence of mild hypoalbuminaemia in isolation is not 
thought to cause pleural effusions(34) and is unlikely if albumin ≥18 u/L , in the presence of other 
disease processes (see Fig. 2) it could be a contributory cause and nutritional supplementation should 
be optimised.  
 
 
 
Figure 2: Pleural effusion in patient with hepatomegaly and cardiomegaly.  
 
Other strategies:  
Dual Phase CTPA  
The clinical diagnosis of pulmonary embolism (PE), particularly in the presence of a pleural effusion, 
can be difficult(35). A prospective trial investigating the incidence of PEs in consecutive patient with a 
unilateral effusions, with a dual phase CTPA (35), found the incidence of concurrent PEs was low (6.4%) 
and in no cases was it felt to be the leading cause of the effusion. PE was only clinically suspected in 
one case. It was more frequent (9.8%) in patients who were subsequently diagnosed with pleural 
malignancy. Malignancy is an independent risk factors for venous thromboembolic disease(VTE) (36), 
increasing the overall risk 7-fold in patients with cancer, and 22 fold in patients with lung cancer(37).  
This study demonstrates that PEs are uncommon in unilateral effusions, however if it does occur, it is 
frequently associated  with malignancy(35).  
A dual phase CT, incorporating CTPA and pleural phase imaging may allow both the investigation of 
the pleural and exclusion of PE, and would be recommended if pleural malignancy is suspected. A 
CTPA could also be considered if breathless does not improve post aspiration or there are features on 
fluid analysis suggestive of PE-related effusion (high haemocrit, neutrophilic). Conversely, the pleural 
effusion secondary to a pulmonary embolism are typically small (see Figure 3), and a larger effusions 
should prompt investigation for a concomitant cause (31) 
 
 
Figure 3: Pulmonary embolism and malignant pleural effusion  
 
Pleural manometry in the unexpandable lung 
Understanding the pathophysiology of the unexpandable lung can be used to demonstrate dual 
pathology in pleural disease(38). Chopra et al demonstrated this, in a patient with a pressure/volume 
curve consistent with entrapped lung, but with an transudative effusion, they could demonstrate an 
effusions of mixed aetiologies(38).Whilst this will be of limited use in the majority of patients, in is a 
good example of the use of basic science in making the diagnosis in a complex patient.  
 
 
Management 
The identification or one or more contributory cause to a pleural effusion should prompt consideration 
for change of management pathway. For some disease processes, there would be strong justification 
of additional management. The identification of concurrent thromboembolic disease, pleural 
Pulmonary 
embolism 
infection, or malignancy should prompt instigation of appropriate management. The presence of heart 
failure or hypoalbuminaemia, may act as ‘coupling factors’ for the common exudates (malignancy and 
infection), promoting more rapid accumulation. And the use of diuretics in CHF and treatment of 
hypoalbuminaemia should be considered to decrease rate of fluid re-accumulation. However, it has 
not been established that optimising organ dysfunction, for example CHF with malignant pleural 
effusion, would lead to improved outcomes (4). This would need to be subject to future interventional 
control trials. The identification of more than one cause may have an effect on prognosis. A study by 
DeBiasi demonstrated that the mortality of patients with multiple benign aetiologies was higher (55% 
1 year mortality) than those from single benign aetiology(39), and a high serum NT—pro BNP has been 
shown to be independently associated with poor prognosis in patients with malignant pleural 
effusions(1). 
 
 
Conclusion  
With an aging population and increasing rates of congestive heart disease and malignant pleural 
disease, it is likely there will an increase in the proportion of effusions caused by multiple aetiologies. 
Understanding that there are potentially concurrent causes to a pleural effusion is vital in establishing 
the diagnoses. Disease-specific biomarkers will be in key in developing a diagnostic algorithm in the 
complex pleural patient and further work will build upon this. Future studies examining the efficacy 
of treating multiple underlying causes of a pleural effusion, i.e. concurrent cardiac effusions with 
malignant pleural effusion, will help develop management pathways.  
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